Table 1 Characteristics of patients who determined vancomycin therapeutic drug monitoring program (n = 78)
Characteristics | |
 Sex (male/female) | 17/61 |
 Age (years) | 65 [57–63] |
 Body weight (kg) | 79 [71.5–86] |
 Apache II score | 19 [18-22] |
 SOFA score | 13 [12-15] |
 Albumin (g/L) | 28.20 [24.85–32.30] |
 Serum creatinine (μmol/L) | 56.0 [46.0–84.5] |
 Cys-C (mg/L) | 1.105 [0.770–1.418] |
Cancer type, n(%) | |
 Hepatocellular carcinoma | 16 (20.5) |
 Pancreatic cancer | 6 (7.7) |
 Colorectal cancer | 22 (28.2) |
 Gastric cancer | 32 (41.0) |
 Gallbladder cancer | 2 (2.6) |
Tumor stage, n(%) | |
 I | 0 (0) |
 II | 7 (9.0) |
 III | 56 (71.8) |
 IV | 15 (19.2) |
Suspected source of infection, n(%) | |
 Pulmonary | 39 (50.0) |
 Intra-abdominal | 28 (35.9) |
 Surgical incision | 3 (3.8) |
 Other/unknown | 8 (10.3) |
Identified pathogens, n(%) | |
 methicillin-resistant Staphylococcus aureus | 11 (14.1) |
 methicillin-resistant Staphylococcus epidermidis | 16 (20.5) |
 methicillin-sensitive Staphylococcus aureus | 17 (21.8) |
 Enterococcus | 29 (37.2) |
 Other Gram-positive coccus | 5 (6.4) |
Concomitant antibioticsa, n(%) | |
 Beta-lactam | 31 (39.7) |
 Carbapenem | 47 (60.3) |
 Antifungal | 8 (10.3) |
 None | 3 (3.8) |